ASE president shares his vision | Heartflow files for IPO | Cardiology still leading the way | AI for cardiac amyloidosis

American Society of Echocardiography President David H. Wiener, MD, said one of his biggest goals is to help the group thrive in the face of ongoing workforce challenges. He also hopes to get new members involved.

Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

Cardiology continues to be one of the most influential healthcare specialties when it comes to utilizing artificial intelligence. 

The first FDA-cleared AI model of its kind was found to be an accurate screening tool for cardiac amyloidosis.

One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.

A team of biomedical engineers, radiologists and cardiologists has developed a new AI model capable of restoring low-quality cardiac MRI scans.

The new guidelines detail the use of echocardiography to evaluate patients for a variety of conditions.

RSNA and several other industry societies have shared a new expert consensus document on the significant value of cardiac CT. Echo remains an effective first-line imaging option, the groups wrote, but CT can make a big impact as well.